Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Top Page
Sunshine Biopharma
(NASDAQ:SBFM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-18.70% Downside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by weak financial performance—ongoing net losses and persistent negative operating/free cash flow—despite reasonable gross margins and modest leverage. Technicals are mixed with short-term stabilization but a longer-term downtrend, valuation is constrained by negative earnings (negative P/E), and a recent negative corporate event (sudden COO resignation) adds incremental risk.
Positive Factors
Reasonable gross margins
Sustained gross margins near 31–39% indicate the core product economics are viable for a generics specialist. Durable unit economics provide a runway to reach profitability if operating expenses are controlled and scale continues, supporting margin sustainability over a multi‑quarter horizon.
Negative Factors
Persistent negative cash flow
Consecutive annual operating and free cash flow deficits create structural cash burn that increases reliance on external financing. Over months this erodes runway, forces dilutive raises or expensive financing, and constrains the firm's ability to invest in commercialization or R&D without clear path to self‑funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Reasonable gross margins
Sustained gross margins near 31–39% indicate the core product economics are viable for a generics specialist. Durable unit economics provide a runway to reach profitability if operating expenses are controlled and scale continues, supporting margin sustainability over a multi‑quarter horizon.
Read all positive factors
Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.10M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth13.24%
EPS Growth98.80%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.19
Shares Outstanding4,905,945
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.96
Enterprise Value/Market Cap-0.67
Enterprise Value/Revenue-0.09
Enterprise Value/Gross Profit-0.28
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$50.00M
Sunshine Biopharma Business Overview & Revenue Model
Company Description
Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug ...
How the Company Makes Money
Sunshine Biopharma primarily makes money by commercializing pharmaceutical products, especially generic prescription drugs, and recognizing revenue from product sales into its distribution channels. Key revenue streams typically include: (1) sales...
Sunshine Biopharma Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.31M | 34.87M | 24.09M | 4.35M | 228.43K |
| Gross Profit | 11.92M | 10.67M | 8.34M | 1.70M | 110.60K |
| EBITDA | -4.15M | -5.15M | -3.82M | -26.45M | -12.10M |
| Net Income | -5.98M | -5.13M | -4.51M | -26.74M | -12.44M |
Balance Sheet | |||||
| Total Assets | 30.08M | 30.56M | 27.35M | 29.55M | 2.20M |
| Cash, Cash Equivalents and Short-Term Investments | 9.12M | 9.69M | 16.29M | 21.83M | 2.05M |
| Total Debt | 812.42K | 952.48K | 657.71K | 765.26K | 1.90M |
| Total Liabilities | 7.04M | 7.06M | 6.14M | 7.92M | 1.99M |
| Stockholders Equity | 23.04M | 23.50M | 21.21M | 21.63M | 211.66K |
Cash Flow | |||||
| Free Cash Flow | -5.51M | -14.85M | -9.56M | -5.55M | -1.83M |
| Operating Cash Flow | -5.33M | -12.53M | -8.78M | -5.25M | -1.83M |
| Investing Cash Flow | -836.31K | -2.32M | -656.15K | -14.62M | 0.00 |
| Financing Cash Flow | 4.75M | 9.29M | 3.43M | 39.47M | 2.90M |
Sunshine Biopharma Technical Analysis
Negative
1.23
Price Trends
1.13
Negative
1.25
Negative
1.41
Negative
Market Momentum
-0.02
Negative
45.16
Neutral
25.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.23 is above the 20-day moving average (MA) of 1.06, above the 50-day MA of 1.13, and below the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.16 is Neutral, neither overbought nor oversold. The STOCH value of 25.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.
Sunshine Biopharma Risk Analysis
Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted Q4, 2023
Sunshine Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.17M | -1.90 | -85.94% | ― | 25.02% | 55.11% | |
45 Neutral | $6.86M | -10.73 | -40.66% | ― | -1.50% | 80.17% | |
44 Neutral | $5.10M | -0.86 | -24.34% | ― | 13.24% | 98.80% | |
40 Underperform | $2.21M | -0.26 | -93.87% | ― | -0.74% | 81.49% | |
| ― | $4.05M | -0.25 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
SBFM
Sunshine Biopharma
1.04
-0.32
-23.53%
SNOA
Sonoma Pharmaceuticals
2.41
0.12
5.24%
YCBD
cbdMD
0.65
-1.10
-62.69%
IMCC
IM Cannabis Corp
0.36
-1.02
-74.09%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.73
-8.43
-92.08%
Sunshine Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sunshine Biopharma Engages Aegis for Warrant Solicitation
Neutral
Mar 9, 2026
On March 6, 2026, Sunshine Biopharma Inc. signed a three‑month engagement agreement with Aegis Capital Corp. for Aegis to act as warrant solicitation agent on a best‑efforts basis to induce the exercise of the company’s outstandi...
Shareholder MeetingsStock Split
Sunshine Biopharma Shareholders Approve Potential Reverse Stock Split
Neutral
Feb 20, 2026
On February 18, 2026, Sunshine Biopharma Inc. reported that CEO Dr. Steve N. Slilaty, as majority voting shareholder, approved a written consent authorizing the board to implement a reverse split of the company’s common stock at a ratio of u...
Business Operations and StrategyExecutive/Board Changes
Sunshine Biopharma Announces Sudden Resignation of Chief Operating Officer
Negative
Feb 5, 2026
On February 5, 2026, Sunshine Biopharma Inc. announced that its chief operating officer, Dr. Abderrazzak Merzouki, resigned from his position with immediate effect, marking an abrupt change in the company’s senior leadership structure. The s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.